Zobrazeno 1 - 6
of 6
pro vyhledávání: '"E V Kariagina"'
Autor:
S V Gritsaev, I S Martynkevich, I S Ziuzgin, E V Kariagina, L S Martynenko, E V Petrova, N Iu Tsybakova, M P Ivanova, I I Kostroma, S A Tiranova, N A Potikhonova, K M Abdulkadyrov
Publikováno v:
Терапевтический архив, Vol 86, Iss 7, Pp 45-52 (2014)
AIM. To characterize the clinical and hematological variability of acute myeloid leukemia (AML) with t(8;21) and to identify the signs associated with the likelihood of its relapse. MATERIALS AND METHODS. The results of examining 44 patients aged 11
Externí odkaz:
https://doaj.org/article/c9705188e8214ff487de5afa236d89e1
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, E. I. Podoltseva, E. V. Kariagina, G. N. Salogub, А. S. Nisamutdinova, L. M. Matuhina, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 61-66 (2022)
Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a me
Externí odkaz:
https://doaj.org/article/8553a7bdc296417c8a2e1b3fa806ced5
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, N. V. Stepanova, K. M. Abdulkadyrov, G. N. Salogub, E. R. Machulaitene, E. V. Kariagina
Publikováno v:
Онкогематология, Vol 0, Iss 2, Pp 40-45 (2022)
We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 6
Externí odkaz:
https://doaj.org/article/b683f210247445cdb987afa77e18fa09
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, E. V. Kariagina, N. V. Stepanova, G. N. Salogub, T. L. Shelkovskaya, T. A. Malakhova, I. A. Skorokhod, E. I. Podoltseva, N. O. Saraeva, O. I. Kovalev, A. V. Klimovich, N. V. Medvedeva, K. M. Abdulkadyrov, L. I. Krylova, T. H. Potrachkova, M. A. Novikova, E. R. Machulaitene, E. I. Darskaya, L. M. Matukhina, N. A. Kotova, O. Ya. Kostina, I. A. Novokreshchenova
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 6-13 (2022)
We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate
Externí odkaz:
https://doaj.org/article/c2efdc3ba2154cfb809d445aa9adf43d
Autor:
A. M. Chekalov, M. O. Popova, I. V. Tsygankov, Yu. A. Rogacheva, N. P. Volkov, K. V. Lepik, M. V. Demchenkova, T. V. Schneider, Yu. V. Kopeikina, N. V. Medvedeva, I. S. Zyuzgin, E. S. Pavlyuchenko, A. N. Levanov, A. A. Myasnikov, E. V. Kariagina, N. B. Mikhailova, V. V. Baykov, A. D. Kulagin
Publikováno v:
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 29, Iss 3, Pp 65-73 (2022)
Introduction. The risk of developing Hodgkin lymphoma (HL) with HIV infection is higher than in the general population, and the course of the disease itself is more aggressive. Currently, there is no unified approach to the treatment of HIV-related H
Externí odkaz:
https://doaj.org/article/ea9ed8309c9d4e90a602283379e9c436
Autor:
S. S. Bessmeltsev, E. V. Kariagina, L. V. Stelmashenko, G. N. Salogub, E. R. Machulaitene, K. M. Abdulkadyrov, N. A. Kotova, I. I. Kostroma, N. V. Medvedeva, L. I. Krylova, E. Yu. Ilushkina
Publikováno v:
Онкогематология, Vol 7, Iss 1, Pp 6-14 (2014)
We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34 patients with relapsed and refractory myeloma. For patients who received lenalidomide the over
Externí odkaz:
https://doaj.org/article/e2a2f3e21b514fa3bcb826edeb7fa3e9